Corporate Snapshot

Cytomedix, Inc. ("the Company") is a biotechnology company specializing in the research, development, licensing, and distribution of biological therapies for tissue repair. Its initial product utilizes autologous platelet releasate therapies (i.e. therapies using the patient's own body products) for the treatment of open, cutaneous tissue. This technology, which uses growth factors and other releasates from human platelets to heal tissue due to acute and chronic wounds, is employed by several companies in products—some of which are sold under license by Cytomedix. The Company's proprietary and patented product, called the AutoloGel™ System, has been used for treating chronic wounds. Cytomedix is in the final stages of a pivotal clinical trial that is designed to evaluate the efficacy and safety of its technology for specific wound healing indications, which would enable the Company to make claims for healing specific types of wounds and would facilitate a coverage decision for Medicare reimbursement. The AutoloGel™ System is unique in that it uses the patient's own plasma, platelets, and other essential blood components, which are separated through a centrifugation process and formed into a gel (AutoloGel™), and applied to the patient's wound under the direction of a physician. AutoloGel™ is similar to the body's natural healing process as it maintains a moist wound environment that introduces multiple growth factors into the wound bed through the gel, and provides a cellular matrix on which new tissue can grow. Data on AutoloGel™ received from clinicians has documented wound healing versus non-healing while treating patients with previous traditional treatment modalities. Also, clinicians and healthcare managers have reported the cost effectiveness of AutoloGel™ versus other treatment modalities for chronic wounds.

* The Corporate Snapshot was last updated on January 23, 2006.

Latest Research

Quarterly
Update

2006-01-23

Click to View

Executive
Informational
Overview

2005-08-24

Click to View

Stock Information (CMXI.OB)